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Abstract: Heart failure (HF) is a major health care issue, and the incidence of HF is only expected to
grow further. Due to the frequent hospitalizations, HF places a major burden on the available hospital
and healthcare resources. In the future, HF care should not only be organized solely at the clinical
ward and outpatient clinics, but remote monitoring strategies are urgently needed to guide, monitor,
and treat chronic HF patients remotely from their homes as well. The intuitiveness and relatively
low costs of non-invasive remote monitoring tools make them an appealing and emerging concept
for developing new medical apps and devices. The recent COVID-19 pandemic and the associated
transition of patient care outside the hospital will boost the development of remote monitoring tools,
and many strategies will be reinvented with modern tools. However, it is important to look carefully
at the inconsistencies that have been reported in non-invasive remote monitoring effectiveness. With
this review, we provide an up-to-date overview of the available evidence on non-invasive remote
monitoring in chronic HF patients and provide future perspectives that may significantly benefit the
broader group of HF patients.
Keywords: remote monitoring; non-invasive monitoring; telemonitoring; heart failure
1. Introduction
Worldwide, approximately 26 million patients are currently diagnosed with heart
failure (HF), and this population is rapidly growing [1]. Several factors, including an
increase in awareness, improved diagnostic techniques, improved survival of coronary
artery disease, increase in the prevalence of HF-related comorbidities such as hypertension
and diabetes mellitus, and an aging population, contributes to this growth [2]. HF manage-
ment places a major burden on healthcare resources due to frequent hospitalizations and
outpatient visits [3]. Additionally, chronic HF is associated with increased mortality and
morbidity [4].
Timely detection of congestion due to HF can prevent HF-related hospitalization,
reduce the overall burden on health care resources, and improve patient outcomes [5,6].
Remote monitoring could be a crucial tool for the early detection of deterioration of HF.
Furthermore, remote monitoring could also be used to stratify which patients are at high
risk for deterioration and need frequent follow-up or outpatient attention and those who
are at low risk and require less regular follow-up. It has been shown that the uptake and
titration of guideline-recommended medical HF therapy could be improved further [7–10].
Remote monitoring strategies can be used to aid clinicians in the up-titration of guideline-
recommended medical HF therapy [11]. Over the last years, multiple monitoring strategies,
such as non-invasive remote monitoring (consisting of structured telephone support or
non-invasively monitoring of parameters including body weight, blood pressure, and
heart rate), monitoring using cardiac implantable electronic devices (such as implantable
cardioverter-defibrillator or cardiac resynchronization therapy devices) and invasive re-
mote hemodynamic monitoring, have been proposed and tested [12–14]. Considering the
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surge in medical technology apps, which will be boosted by the recent COVID-19 pandemic,
it is essential to have an updated overview of the available tools and their evidence. In
this review, we will focus on non-invasive remote monitoring tools in HF patients. Stud-
ies investigating non-invasive remote monitoring strategies can be divided into studies
that have compared usual care with (I) structured telephone support or (II) non-invasive
telemonitoring. In the case of non-invasive telemonitoring, patients were instructed to
measure specific parameters (such as body weight, heart rate, or blood pressure), which
were automatically sent to their health care team. In 2015 a Cochrane meta-analysis assess-
ing the effects of both non-invasive remote monitoring strategies in chronic HF patients
had been updated [12]. This Cochrane review reported a significant reduction in all-cause
mortality for both structured telephone support, as well as non-invasive telemonitoring
(Risk Ratio (RR) 0.87 (0.77–0.98) and RR 0.80 (0.68–0.94), resp.) and a significant reduction
in HF-related hospitalizations (RR 0.85 (0.77–0.93) and RR 0.71 (0.60–0.83), resp.). However,
the effects were relatively small and not convincingly positive, with the vast majority of
studies being negative. This is important when new apps and e-health tools are developed
based on old principles. However, since then, several new studies have been published
which have reported more positive results if a structured approach is used in specific
populations. Therefore, this review aims to provide an overview of the currently available
evidence on both non-invasive remote monitoring strategies of chronic HF patients.
2. Methods for Study Selection
We included randomized controlled trials as well as clinical studies comparing HF
management delivered via structured telephone support or non-invasive home telemon-
itoring with usual post-discharge care for people with heart failure living within the
community. We included only studies that have been published in full in the peer-reviewed
literature. We excluded any studies that did not report data for any of our outcomes of
interest in an extractable format (all-cause mortality, all-cause hospitalization, HF-related
hospitalization, or quality of life) or those who used home visits or additional outpatient
clinics. Additionally, all included studies reported data of only adult patients (aged 18 years
or older) of either sex, any ethnic group, with a definitive diagnosis of HF. Patients could
have been recently discharged from a cardiac clinic after an episode of decompensation
or being recruited in a stable setting from outpatient clinics, as well as studies reporting
data on general cardiac or chronic disorder rather than specifically HF. A combination of
the following search terms were used: ‘heart failure’, ‘heart or cardiac or myocard’, and
‘failure or insufficiency or decompensation’, in combination with ‘telemedicine’, ‘telecom-
munication’, ‘telemonitoring’, ‘teleconsult’, ‘telehealth’, ‘home monitoring’, ‘home care’,
‘ambulatory monitoring’, ‘telehome’, ‘ehealth’ or ‘mobile health’.
We searched the MEDLINE, pubmed, database on 1 September 2020, and performed
the following. All titles and abstracts were checked for relevance to the review topic by
two authors, independently. In case of disagreement, a third author would check the article
as well. All data relevant data were extracted from the articles.
3. Structured Telephone Support versus Usual Care
We identified 31 studies that compared structured telephone support with usual care,
which included a total of 11,270 patients [15–45]. The study characteristics, as well as
the reported outcomes on all-cause mortality, all-cause hospitalization, and HF-related
hospitalization rates of the five largest studies, representing 49% (5560) of all patients, will
be discussed in detail below [19,21–23,34]. The study characteristics and outcomes of the
other 26 studies will be summarized below.
3.1. Chaudhry et al. (Tele-HF Trial)
In 2010, Chaudhry et al. published the results from the Telemonitoring to Improve
Heart Failure Outcomes (Tele-HF) trial, including 1653 recently hospitalized chronic (e.g.,
unstable) HF patients with a median age of 61 years, 58% were men, and 57% were in the
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New York Heart Association (NYHA) class III or higher [23]. The prescribed background
was relatively low, with 79% of patients receiving a beta-blocker, 67% a renin-angiotensin
system (RAS)-inhibitor, and only 33% a mineralocorticoid receptor antagonist (MRA).
The patients were followed for six months. During this period, no significant differences
in the all-cause mortality (odds ratio (OR) 0.98 (0.75–1.28), all-cause hospitalization (OR
1.08 (0.89–1.31)) or HF-related hospitalization rates (OR 1.04 (0.84–1.30)) were observed.
Overall, a marginal, non-significant reduction in all-cause mortality and both all-cause
and HF-related hospitalizations occurred more often in HF patients receiving structured
telephone support.
3.2. Ferrante et al. (DIAL Trial)
The results from the Randomized Trial of Phone Intervention in Chronic Heart Failure
(DIAL) were published in 2010 by Ferrante et al. [22]. They included 1518 stable chronic
HF patients, with a mean age of 65 years, 71% were men, and 49% were in an NYHA class
III or IV. The prescribed background was relatively low; only 62% received a beta-blocker,
93% a RAS-inhibitor, and 32% an MRA. All patients were followed for 12 months; during
this period, no significant reduction in all-cause mortality (OR 0.95 (0.75–1.20)) or all-cause
hospitalizations (OR 0.82 (0.66–1.01)) were observed. However, a significant reduction in
the number of HF-related hospitalizations was reported (OR 0.71 (0.55–0.91)) in patients
receiving structured telephone support.
3.3. Galbreath et al.
Galbreath et al. included 1069 stable chronic HF patients, with a mean age of 71 years,
71% were men, and 24% were in an NYHA class III or IV and reported their results in
2004 [34]. The background therapy was not frequently prescribed, with 47% of patients
receiving a beta-blocker and 73% receiving a RAS-inhibitor. No data on MRA prescription
rates were reported. The follow-up duration was 18 months, and during this period, no
significant difference in the all-cause mortality rates (OR 0.70 (0.47–1.04)) was reported.
The study did not report data on all-cause or HF-related hospitalization rates.
3.4. Angermann et al. (INH Study)
The results from the Interdisciplinary Network for Heart Failure (INH) study per-
formed by Angermann et al. was published in 2012 [19]. A total of 715 unstable HF patients
(mean age 69 years, 71% males and 40% in an NYHA class III or higher) were included.
These patients frequently received background HF therapy; 80% received a beta-blocker,
88% a RAS-inhibitor, and 42% an MRA. A significant reduction in the all-cause mortality
rates (OR 0.63 (0.42–0.96)) was observed during the six month follow-up period in patients
receiving structured telephone support. No significant differences were observed in the
all-cause or HF-related hospitalization rates (OR 1.14 (0.84–1.57) and OR 0.79 (0.49–1.25),
respectively).
3.5. Baker et al.
In 2011, Baker et al. published the results of their study, including 605 stable chronic
HF patients (mean age 61 years, 52% were men, and 31% were in an NYHA class III/IV) [21].
Many patients received HF background therapy; a beta-blocker was prescribed in 81%,
RAS-inhibitor in 82%, and MRAs in 27%. The patients were followed for one month, and
during this period, no significant difference in the all-cause mortality was observed (OR
0.20 (0.01–4.13)) between HF patients receiving usual care or structured telephone support.
The study did not report data on all-cause or HF-related hospitalization rates.
3.6. Other Studies
A summary of the study characteristics for the 26 other structured telephone support
studies is shown in Table 1. As shown, large differences in the sample sizes and patient
demographics exist between the studies. Between 20 to 462 patients were included in these
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studies, with a mean age ranging from 57 to 76 years. The follow-up duration ranged
from three to 12 months. Additionally, significant differences in the reported background
therapy were reported. Between 4% to 87% of the patients with structured telephone
support received a beta-blocker, 54% to 95% received a renin-angiotensin system (RAS)
inhibitors, and 6% to 63% received a mineralocorticoid receptor antagonist (MRA).
Of the 26 other studies, 24 studies reported data on the all-cause mortality, these results
are shown in Table 2/Figure 1 [15,17,18,20,24,25,27–33,35–45]. As shown, 13 studies did re-
port a non-significant reduction in all-cause mortality [20,25,29,30,32,35–38,40,41,43,45], while
11 studies did not show a reduction in the all-cause mortality [15,17,18,24,27,28,31,33,39,42,44].
Figure 1. All-cause mortality in patients receiving structured telephone support versus usual care.
Sixteen of the other studies reported data on all-cause hospitalization rates, as shown in
Table 2/Figure 2 [15,17,18,20,24,25,27–29,31–33,35,37,38,45]. Of these studies, five demon-
strated a significant reduction in the all-cause hospitalization rates [17,25,27,31,45], while
five studies reported a non-significant reduction [20,28,29,32,38]. In contrast, six studies
did not report a beneficial effect [15,18,24,33,35,37].
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Table 1. Baseline characteristics and background HF therapy in studies investigating structured telephone support in HF patients.
Author (Year) Study Acronym Number of Patients Age Male (%) NYHA III/IV (%) Duration of Follow-Up
Background HF Therapy
Beta-Blockers RAS-Inhibitors MRAs
Rahimi et al. (2020) [15] SUPPORT-HF 2 202 71.3 ± 11.1 71.3 40.5 6 months NA NA NA
Gingele et al. (2019) [16] TEHAF 382 71.4 ± 11.2 59.2 42.7 12 months 82.0 89.9 NA
Krum et al. (2013) [17] CHAT 405 73.0 ± 10.5 63.1 41.4 12 months 61.4 84.2 26.1
Boyne et al. (2012) [18] TEHAF 382 71.4 ± 11.2 59.2 42.7 12 months 81.1 89.0 NA
Angermann et al. (2012) [19] INH 715 68.6 ± 12.2 70.6 39.9 6 months 79.9 88.1 41.8
Domingues et al. (2011) [20] 111 63 ± 13 57.7 97.3 3 months NA NA NA
Baker et al. (2011) [21] 605 60.7 ± 13.1 51.9 30.9 1 month 81.3 82.1 27.4
Ferrante et al. (2010) [22] DIAL 1518 65.0 ± 13.3 70.8 49.4 12 months 61.6 92.9 32.2
Chaudhry et al. (2010) [23] Tele-HF 1653 61 (51–73) 58.0 57.3 6 months 79.2 66.9 32.8
Mortara et al. (2009) [24] HHH 461 60 ± 12 85.0 39.9 12 months 87 87 NA
Bento and Brofman (2009) [25] 40 57.5 ± 9.4 70.0 37.5 6 months 85.0 75.0 62.5
Brandon et al. (2009) [26] 20 60 (49–69) 45.0 25.0 3 months NA NA NA
Wakefield et al. (2008) [27] 148 69.3 ± 9.6 98.6 71.6 12 months NA NA NA
Sisk et al. (2006) [28] 406 59.4 ± 13.7 53.7 59.1 12 months 52.0 NA NA
Riegel et al. (2006) [29] 134 72.1 ± 11.0 46.3 81.3 6 months 54.0 74.6 11.1
DeWalt et al. (2006) [30] 123 62.5 ± 10.0 49.2 50.1 12 months 63.3 73.3 NA
Dunagan et al. (2005) [31] 151 70.0 ± 13.3 43.7 80.1 12 months NA 70.2 NA
Cleland et al. (2005) [32] TEN-HMS 426 67.2 ± 11.6 77.2 34.0 8 months 80.9 81.0 49.1
Tsuyuki et al. (2004) [33] 276 71.5 ± 12 58.0 26.4 6 months 42.8 84.8 13.4
Galbreath et al. (2004) [34] 1069 70.9 ± 10.3 71 24 18 months 47 73 NA
DeBusk et al. (2004) [35] 462 72 ± 11 51.1 50.1 12 months NA NA NA
Capomolla et al. (2004) [36] 133 57 ± 10 88.0 33.1 12 months NA 84.2 21.1
Laramee et al. (2003) [37] 287 70.7 ± 11.8 54.4 35.9 3 months NA NA NA
Riegel et al. (2002) [38] 358 73.9 ± 12.4 48.9 96.9 6 months 16.9 53.6 NA
McDonald et al. (2002) [39] 98 70.8 ± 10.5 66.3 2.3 ± 0.6 3 months NA 61.2 NA
Krumholz et al. (2002) [40] 88 73.8 ± 9.5 56.8 NA 12 months 40.9 59.1 NA
Kasper et al. (2002) [41] 200 61.9 ± 14.3 60.5 58.5 6 months 39.0 94.5 NA
Jerant et al. (2001) [42] 37 70.1 ± 12.1 45.9 35.1 12 months 37.8 67.6 27.0
Blue et al. (2001) [43] 165 75.5 ± 8.3 57.6 77.0 12 months 4.2 71.5 5.5
Barth (2001) [44] 34 75.2 ± 8.4 47.1 NA 6 months NA NA NA
Gattis et al. (1999) [45] PHARMA 181 67.2 (55.0–74.5) 68.0 33.1 6 months NA 77.9 NA
HF, heart failure; MRA, mineralocorticoid receptor antagonist; NA, not available; NYHA, New York Heart Association; RAS, renin-angiotensin system.
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Table 2. Clinical outcomes of structured telephone support studies.
Author (Year)
Number of Patients
All-Cause Mortality All-Cause Hospitalization HF-Related Hospitalization






STS UC STS UC STS UC STS UC
Rahimi et al. (2020) [15] 101 101 13 6 2.17 (0.86–5.48) 40 29 1.63 (0.90–2.93) 13 13 1.00 (0.44–2.28)
MLWHFQ
STS −0.30; UC −0.66
p = 0.63
Gingele et al. (2019) [16] 197 185 NA NA NA NA NA NA NA NA NA
EQ-5D
STS +0.01; UC +0.02
p = 0.83
Krum et al. (2013) [17] 188 217 17 16 1.23 (0.64–2.36) 74 114 0.59 (0.39–0.87) 23 35 0.72 (0.41–1.28) NA
Boyne et al. (2012) [18] 197 185 19 12 1.49 (0.74–2.98) 48 35 1.38 (0.84–1.57) 18 25 0.64 (0.34–1.22) NA
Angermann et al. (2012) [19] 352 363 32 52 0.63 (0.42–0.96) 119 112 1.14 (0.84–1.57) 36 46 0.79 (0.49–1.25)
SF-36—physical health




STS +5.9; UC +1.8
p = 0.03
Domingues et al. (2011) [20] 57 63 8 13 0.68 (0.30–1.52) 20 23 0.94 (0.45–1.99) NA NA NA
Baker et al. (2011) [21] 303 302 0 2 0.20 (0.01–4.13) NA NA NA NA NA NA
ICICE HFSS
STS +6.7; UC −0.1
p < 0.01
Ferrante et al. (2010) [22] 760 758 116 122 0.95 (0.75–1.20) 261 296 0.85 (0.66–1.01) 128 169 0.71 (0.55–0.91)
MLWHFQ
STS −35.0; UC −30.6
p < 0.01
Chaudhry et al. (2010) [23] 826 827 92 94 0.98 (0.75–1.28) 407 392 1.08 (0.89–1.31) 227 223 1.04 (0.84–1.30) NA
Mortara et al. (2009) [24] 94 160 7 9 1.32 (0.51–3.44) NA NA NA 17 28 1.04 (0.54–2.02) NA
Bento and Brofman (2009) [25] 20 20 0 1 0.33 (0.01–7.72) NA NA NA NA NA NA NA
Brandon et al. (2009) [26] 10 10 NA NA NA NA NA NA NA NA NA
MLWHFQ
STS −18.7; UC +6.6
p = 0.03
Wakefield et al. (2008) [27] 99 49 25 11 1.12 (0.60–2.09) 41 29 0.49 (0.24–0.98) 51 29 0.73 (0.37–1.46)
MLWHFQ
STS −16.9; UC −4.0
p = NS
Sisk et al. (2006) [28] 203 203 22 22 1.00 (0.57–1.75) 62 74 0.77 (0.51–1.16) 18 29 0.58 (0.31–1.09)
MLWHFQ




STS 39.9; UC 36.3
Difference 3.2
(1.0–5.3)
Riegel et al. (2006) [29] 70 65 6 8 0.70 (0.26–1.90) 39 37 0.95 (0.48–1.88) 21 22 0.84 (0.41–1.73)
MLWHFQ
STS −40.6; UC −43.2
EQ-5D
STS +0.13; UC +0.12
PHQ-9
STS −7.3; UC −6.6
DeWalt et al. (2006) [30] 62 65 3 4 0.79 (0.18–3.37) NA NA NA 21 25 0.82 (0.40–1.69)
MLWHFQ
STS −1; UC −5
p = 0.59




All-Cause Mortality All-Cause Hospitalization HF-Related Hospitalization






STS UC STS UC STS UC STS UC
Dunagan et al. (2005) [31] 76 75 6 5 1.18 (0.38–3.71) 41 57 0.37 (0.18–0.74) 23 35 0.50 (0.25–0.97) NA
Cleland et al. (2005) [32] 173 85 27 20 0.66 (0.40–1.11) 85 46 0.82 (0.49–1.38) 34 24 0.62 (0.34–1.14) NA
Tsuyuki et al. (2004) [33] 140 136 16 12 1.30 (0.64–2.64) 59 51 1.21 (0.75–1.97) 37 38 0.93 (0.55–1.57) NA
Galbreath et al. (2004) [34] 710 359 54 39 0.70 (0.47–1.04) NA NA NA NA NA NA
SF-36—general health
STS −0.4; UC +0.2
p = 0.87
DeBusk et al. (2004) [35] 228 234 21 29 0.74 (0.44–1.26) 116 117 1.04 (0.72–1.49) 38 43 0.89 (0.55–1.57) NA
Capomolla et al. (2004) [36] 67 66 5 7 0.70 (0.24–2.11) 17 58 0.05 (0.02–0.12) NA
Laramee et al. (2003) [37] 141 146 13 15 0.90 (0.44–1.82) 49 46 1.16 (0.71–1.89) 18 21 0.87 (0.44–1.71) NA
Riegel et al. (2002) [38] 130 228 16 32 0.88 (0.50–1.54) 56 114 0.76 (0.49–1.17) 23 63 0.56 (0.33–0.96) NA
McDonald et al. (2002) [39] 51 47 3 1 2.76 (0.30–25.67) NA NA NA 1 11 0.07 (0.01–0.53) NA
Krumholz et al. (2002) [40] 44 44 9 13 0.69 (0.33–1.45) NA NA NA 12 21 0.41 (0.17–1.00) NA
Kasper et al. (2002) [41] 102 98 7 13 0.52 (0.22–1.24) NA NA NA 26 35 0.62 (0.34–1.13)
MLWHFQ
STS −28.3; UC −25.7
p < 0.01
Jerant et al. (2001) [42] 12 12 1 0 3.00 (0.13–67.06) NA NA NA 1 4 0.18 (0.02–1.95) NA
Blue et al. (2001) [43] 84 81 25 25 0.96 (0.61–1.53) NA NA NA 12 26 0.35 (0.16–0.76) NA
Barth (2001) [44] 17 17 0 0 Not estimable NA NA NA 0 0 Not estimable
MLWHFQ
STS −8.2; UC +0.0
p < 0.01
Gattis et al. (1999) [45] 90 91 3 5 0.61 (0.15–2.46) 17 30 0.47 (0.24–0.94) 1 11 0.08 (0.01–0.65) NA
CI, confidence interval; EQ-5D, EuroQoL 5D; GHQ, general health questionnaire; ICICE HFSS, Improving Chronic Illness care evaluation heart failure symptom scale; MLWHFQ, Minnesota Living with Heart
Failure Questionnaire; NA, not available; NS, not significant; OR, odds ratio; PHQ-9, patient health questionnaire-9; SF-36, Short Form survey 36-item; STS, structured telephone support; UC, usual care.
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Figure 2. All-cause hospitalization in patients receiving structured telephone support versus usual care.
Twenty-two of the 26 other studies reported data on the HF-related hospitalization
rates, and are shown in Table 3/Figure 3 [15,17,18,24,27–33,35–45]. Of these studies, six
reported a significant reduction in the HF-related hospitalization rates [31,36,38,39,42,45],
while 13 studies showed a non-significant reduction [17,18,27–30,32,33,35,37,40–42]. In
contrast, three studies reported no beneficial effect [15,24,44].
Figure 3. Heart Failure (HF)-related hospitalizations in patients receiving structured telephone
support versus usual care.
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3.7. Quality of Life, Symptoms, and Functional Performance
A variety of questionnaires, including Short Form 12 Item (SF-12), Short Form 36 Item
(SF-36), Minnesota Living with Heart Failure Questionnaire (MLWHFQ), EuroQol five-
dimension scale (EQ-5D), Patient Health Questionnaire-9 (PHQ-9), and other tools were
used to evaluate the quality of life.
Thirteen studies have assessed the effects of structured telephone support on the
quality of life. The quality of life of patients who received structured telephone support
improved significantly more than standard care in seven studies [19,21,22,26,28,41,45],
and non-significantly in one study [27]. In contrast, five studies did not show a larger
improvement in the quality of life [15,16,29,30,46].
In total, three of the five studies investigating structure telephone support reported
a significantly bigger improvement of symptoms compared to the usual care [19,34,41],
while two studies did not find a difference [15,32].
Of the two studies reporting functional performance data in patients receiving struc-
tured telephone support, one study demonstrated a bigger improvement in the intervention
group [16], while the other study did not observe a difference [34].
4. Non-Invasive Telemonitoring versus Usual Care
In total, 30 studies investigating non-invasive telemonitoring have been identified,
including a total of 8892 patients [24,32,42,47–73]. The study characteristics, as well as
the reported outcomes on all-cause mortality, all-cause hospitalization, and HF-related
hospitalization rates of the five largest studies, representing 52% (4606) of all patients, will
be discussed in detail below [24,51,52,61,64]. The study characteristics and outcomes of the
other 25 studies will be summarized below [32,42,47–50,53–60,62,63,65–73].
4.1. Koehler et al. (TIM-HF2 Trial)
The results from the Telemedial Interventional Management in Heart Failure II (TIM-
HF2) trial have been published in 2018 by Koehler et al. [51]. In this study, 1571 stable
chronic HF patients (mean age 70 years, 70% was men and 48% were in an NYHA class
III/IV) were randomized towards usual care or remote telemonitoring consisting of daily
transfers of body weight, blood pressure, heart rate, heart rhythm, peripheral capillary
oxygen saturation, and self-rated health status. Many included patients received HF
background therapy; 92% received a beta-blocker, 83% a RAS-inhibitor, and 55% an MRA.
The patients were followed for 12 months, and the compliance with the daily data transfer
was 95% in the intervention patient group. During this period, a significant reduction in
all-cause mortality (OR 0.64 (0.45–0.90) was observed in HF patients receiving non-invasive
telemonitoring, while no beneficial effect on the all-cause hospitalization rates (OR 1.04
(0.84–1.29) was reported. No individual data on HF-related hospitalization were reported.
4.2. Ong et al. (BEAT-HF Trial)
In 2016 Ong et al. published the Better Effectiveness After Transition-Heart Failure
(BEAT-HF) trial [52]. This study included 1437 hospitalized HF patients (median age
74 years, 54% were men and 75% was in an NYHA class III or higher) and randomized
them towards usual care or remote telemonitoring, consisting of daily data transfers of
blood pressure, heart rate, symptoms, and body weight in addition to health coaching
telephone calls and usual care. The use of HF background therapy was relatively low;
beta-blockers were prescribed to 75% of all patients, RAS-inhibitors to 56%, and only 19%
received an MRA. The patients were followed for up to six months. During this period,
the telemonitoring adherence was 51.7% in the patients who were remotely monitored. A
non-significant reduction in all-cause mortality (OR 0.86 (0.64–1.16)) was reported, while no
beneficial effect on the all-cause hospitalization rates (1.07 (0.87–1.31)) was shown in chronic
HF patients receiving non-invasive telemonitoring. Data on HF-related hospitalization
rates were not reported.
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4.3. Koehler et al. (TIM-HF Study)
The Telemedical Interventional Monitoring in Heart Failure (TIM-HF) trial by
Koehler et al., published in 2011, included 710 stable chronic HF patients (mean age
67 years, 81% was male and 50% were in NYHA class III or IV) [61]. These patients were
randomized towards usual care or remote telemonitoring, consisting of electrocardiogram
(ECG), blood pressure, and body weight measurements on top of usual care. Relative a
high percentage of patients received HF background therapy; 93% received a beta-blocker,
95% a RAS-inhibitor, and 64% an MRA. The median follow-up was 26 months. During
this period, 81% of all patients receiving telemonitoring performed at least 70% of all daily
data transfers. During this period no effects on the all-cause mortality (OR 0.99 (0.65–1.48),
all-cause hospitalization (OR 1.17 (0.87–1.57) or HF-related hospitalization rates (OR 0.84
(0.58–1.22)) were observed between HF patients receiving non-invasive telemonitoring or
usual care.
4.4. Mortara et al. (HHH Study)
Mortara et al. published the results from the Home of Hospital in Heart Failure (HHH)
in 2009 [24]. In total 461 stable chronic HF patients (mean age 60 years, 85% were men
and 40% was in NYHA class III/IV) were included and randomized towards usual care
or telemonitoring, consisting of blood pressure, body weight, heart rate, and signs and
symptoms measurements on top of usual care. Many patients received HF background
therapy, with 87% of patients receiving a beta-blocker and RAS-inhibitor. Patients were
followed for 12 months, during this period no reduction in all-cause mortality (OR 1.44
(0.54–3.87)), all-cause hospitalizations (OR 1.24 (0.73–2.10)) or HF-related hospitalizations
(OR 1.02 (0.53–1.96)) were observed in patients receiving non-invasive telemonitoring.
4.5. Giordano et al.
In 2009, Giordano et al. published the results from their study, including 460 unstable
chronic HF patients (mean age 57 years, 85% were men, and 40% was in an NYHA class
III or higher) [64]. The use of background HF therapy was relatively low; 72% of patients
received a beta-blocker, 94% a RAS-inhibitor, and 62% an MRA. The patients randomized
towards telemonitoring received regular remote monitoring using ECG on top of usual
care. The follow-up period was 12 months, during which a significant reduction in the
all-cause mortality (OR 0.39 (0.18–0.82)), all-cause hospitalization (OR 0.57 (0.39–0.84)), and
HF-related hospitalization rates (OR 0.49 (0.32–0.76)) were observed in chronic HF patients
receiving non-invasive telemonitoring compared to patients receiving usual care.
4.6. Other Studies
A summary of the study characteristics for the 25 other structured telephone support
studies is shown in Table 3. As shown, large differences in the sample sizes and patient
demographics exist between the studies. Between 20 to 426 patients were included in these
studies, with a mean age ranging from 54 to 82 years. The follow-up duration ranged from
one to 48 months. Additionally, significant differences in the reported background therapy
were reported. Between 38% to 98% of the patients with structured telephone support
received a beta-blocker, 66% to 100% received a renin-angiotensin system (RAS) inhibitors,
and 21% to 58% received a mineralocorticoid receptor antagonist (MRA).
Twelve of these other studies reported data on monitoring adherence, ranging from
46% up to 95% [47,48,50,54–56,59,60,63,65,69,73]. Importantly to note, the monitoring
strategy’s adherence decreased when the patients had to perform multiple measure-
ments [48,50,73]. Additionally, the adherence decreased over time [48,50,55,56]. Surpris-
ingly, the adherence also decreased in the weeks after hospitalization [47]. These results
highlight that some studies’ adherence was far from optimal and could be even lower in
a ‘real world’ setting. Treating clinicians should reinforce the importance of adherence to
the monitoring strategies by the patients to optimize the effects of non-invasive remote
monitoring strategies.
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Table 3. Baseline characteristics and background HF therapy in studies investigating non-invasive telemonitoring in HF patients.
Author (Year) Study Acronym Intervention Number ofPatients
Age Male (%) NYHA III/IV (%) Duration ofFollow-Up
Background HF Therapy
Beta-Blockers RAS-Inhibitors MRAs
Haynes et al. (2020) [47] BEAT-HF BP, BW, HR, S and S 288 72 (61–83) 52.7 NA 6 months NA NA NA
Ding et al. (2020) [48] ITEC-CHF BW 184 70.1 ± 12.3 76.6 2.1 ± 0.6 6 months 87.5 77.1 57.6
Pekmezaris et al. (2019) [49] BP, BW, HR, SpO2 104 59.9 ± 15.1 58.7 70.2 3 months NA NA NA
Park et al. (2019) [50] BP, BW 58 59.1 ± 13.6 67.2 NA 1 month NA NA NA
Koehler et al. (2018) [51] TIM-HF2 BP, BW, ECG, HR, HS,SpO2 1538 70.0 ± 10.5 69.6 47.5 12 months 91.9 82.5 55.0
Ong et al. (2016) [52] BEAT-HF BP, BW, HR, S and S 1437 73.5 (62.5–83.0) 53.8 74.9 6 months 74.7 55.6 19.3
Vuorinen et al. (2014) [53] BP, BW, S and S 94 58.1 ± 11.8 83.0 61.7 6 months NA NA NA
Villani (2014) et al. [54] ICARLOS BP, BW, HR 80 72 ± 3 73.8 3.0 ± 0.5 12 months NA NA NA
Blum and Gotlieb (2014) [55] MCCD BP, BW, HR 203 72.5 ± 9.0 71.0 85.5 48 months 68.0 66.0 NA
Seto et al. (2012) [56] BP, BW, ECG 100 53.7 ± 13.7 79.0 46.0 6 months 98.0 97.0 52.0
Pekmezaris et al. (2012) [57] BP, Stethoscope 168 82.0 ± 7.0 38.1 20.2 3 months NA NA NA
Lyngå et al. (2012) [58] WISH BW 319 73.6 ± 10.1 74.9 100.0 12 months 92.5 96.2 42.6
Dendale et al. (2012) [59] TEMA-HF 1 BP, BW, HR 160 75.8 ± 9.7 65.0 3.0 ± 0.5 6 months NA NA NA
Wade et al. (2011) [60] BP, BW 316 76.7 ± 7.0 52.2 NA 6 months 81.6 72.0 NA
Koehler et al. (2011) [61] TIM-HF BP, BW, ECG 710 66.9 ± 10.6 81.3 49.9 24 months 92.5 95.4 64.2
Weintraub et al. (2010) [62] SPAN-CHF II BP, BW, HR 188 69.0 ± 13.5 66.0 52.7 3 months 88.3 85.6 20.7
Scherr et al. (2009) [63] BP, BW, HR 108 66 (62–72) 70.8 87.0 6 months 82.4 100.0 40.7
Mortara et al. (2009) [24] HHH BP, BW, HR, S and S 461 60 ± 12 85.0 39.9 12 months 87 87 NA
Giordano et al. (2009) [64] ECG 460 57.0 ± 10.0 85.0 40.4 12 months 72.4 94.3 62.0
Dar et al. (2009) [65] Home-HF BP, BW, SpO2, S and S 182 71.0 ± 11,6 66.5 NA 6 months 56.0 87.9 40.7
Woodend et al. (2008) [66] BP, BW, ECG 121 66.5 ± 12.0 72.0 62.1 12 months NA NA NA
Soran et al. (2008) [67] BW, S and S 315 76.5 ± 7.0 35.3 41.6 6 months 80.3 97.4 NA
Kashem et al. (2008) [68] BP, BW, HR, S and S 48 53.5 ± 10.5 74.0 57.5 12 months NA NA NA
Balk et al. (2008) [69] BP, BW 214 66 (33–87) 70.1 51.9 8 months 80.0 95.3 47.2
Antonicelli et al. (2008) [70] BP, BW, ECG, HR, UO 57 78.0 ± 7.0 61.4 42.1 12 months NA NA NA
Cleland et al. (2005) [32] TEN-HMS BP, BW, ECG, HR 426 67.2 ± 11.6 77.2 34.0 8 months 80.9 81.0 49.1
Goldberg et al. (2003) [71] WHARF BW 280 59.1 ± 15.3 67.5 100.0 6 months 37.5 89.6 NA
Benatar et al. (2003) [72] BP, BW, HR, SpO2 216 63.1 ± 12.9 37.0 3.1 ± 0.3 12 months 53.2 83.8 NA
Jerant et al. (2001) [42] BW, Stethoscope, Sand S 37 70.1 ± 12.1 45.9 35.1 12 months 37.8 67.6 27.0
de Lusignan et al. (2001) [73] BP, BW, HR 20 75.2 NA 1.8 (1–4) 12 months NA NA NA
BP, blood pressure; BW, body weight, ECG, electrocardiogram; HF, heart failure; HR, heart rate, HS, health status questions; MRA, mineralocorticoid receptor antagonist; NA, not available; NYHA, New York
Heart Association; RAS, renin-angiotensin system; SpO2, oxygen saturation; S and S, signs and symptoms; UO, 24 h urine output.
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Of the 25 other studies, 20 studies reported data on the all-cause mortality, these
results are shown in Table 4/Figure 4 [32,42,48,53–56,58–60,62,63,65–71,73]. As shown, two
studies reported a significant reduction [59,71], ten studies did report a non-significant
reduction in all-cause mortality [32,54,55,58,60,62,63,67,70,73], while eight studies did not
show a reduction in the all-cause mortality [42,48,53,56,65,66,68,69].
Figure 4. All-cause mortality in patients receiving non-invasive telemonitroing versus usual care.
Seventeen of the other studies reported data on all-cause hospitalization rates, as
shown in Table 4/Figure 5 [32,42,48,53,55–60,62,65–67,70,71]. Of these studies, two demon-
strated a significant reduction in the all-cause hospitalization rates [63,70], while seven
studies reported a non-significant reduction [32,42,53,58,59,62,65]. In contrast, eight studies
did not report a beneficial effect [48,55–57,60,66,70,71].
Thirteen of the 25 other studies reported data on the HF-related hospitalization rates,
and are shown in Table 4/Figure 6 [32,42,48,53,54,57,59,62,63,65,67,68,72]. Of these studies,
three reported a significant reduction in the HF-related hospitalization rates [54,59,68],
while nine studies showed a non-significant reduction [32,42,53,57,62,63,65,67,72]. In con-
trast, only one study reported no beneficial effect [48].
4.7. Quality of Life, Symptoms, and Functional Performance
Seventeen studies investigating non-invasive telemonitoring reported data on the qual-
ity of life. Seven of these studies reported a significantly larger improvement in the quality
of life compared to the standard care [48,52,54,56,61,67,70], while four studies demon-
strated a non-significant difference [60,71–73]. In total, six studies did not demonstrate a
beneficial effect on the quality of life [49,51,55,65,66,69].
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Table 4. Clinical outcomes of non-invasive telemonitoring studies.
Author (Year)
Number of Patients
All-Cause Mortality All-Cause Hospitalization HF-Related Hospitalization






TM UC TM UC TM UC TM UC
Haynes et al. (2020) [47] 292 NA NA NA NA NA NA NA NA NA NA NA
Ding et al. (2020) [48] 91 93 2 1 2.07 (0.18–23.21) 73 58 2.45 (1.26–4.76) 15 8 2.10 (0.84–5.22)
EQ-5D
TM +4.05; UC +1.10
p = 0.13
Pekmezaris et al. (2019) [49] 46 58 NA NA NA NA NA NA 7 9 0.98 (0.33–2.86)
MLWHFQ
TM −26.4; UC −32.1
p = 0.50
PHQ-9
TM −2.2; UC −3.0
p = 0.43
Park et al. (2019) [50] 60 NA NA NA NA NA NA NA NA NA NA NA
Koehler et al. (2018) [51] 796 775 61 89 0.64 (0.45–0.90) 262 248 1.04 (0.84–1.29) NA NA NA
MLWHFQ
TM −3.08; UC −1.98
p = 0.26
Ong et al. (2016) [52] 715 722 92 106 0.86 (0.64–1.16) 363 355 1.07 (0.87–1.31) NA NA NA
MLWHFQ
TM −32.6; UC −28.5
p = 0.02
Vuorinen et al. (2014) [53] 47 47 0 0 Not estimable 9 13 0.62 (0.24–1.63) 8 13 0.54 (0.20–1.45) NA
Villani et al. (2014) [54] 40 40 5 9 0.49 (0.15–1.63) NA NA NA 12 23 0.32 (0.13–0.80)
PHQ-9
TM −2.8; UC +3.8
p < 0.01
Blum and Gotlieb (2014) [55] 104 102 49 45 1.13 (0.65–1.95) 80 74 1.26 (0.67–2.37) NA NA NA
SF-36—physical health
TM +1; UC +3
p = NS
SF-36—mental health
TM +3; UC +6
p = NS
MLWFHQ
TM −18; UC −19
p = NS
Seto et al. (2012) [56] 50 50 3 0 7.44 (0.37–147.92) 14 10 1.56 (0.61–3.93) NA NA NA
MLWHFQ
TM −8.9; UC −0.5
p = 0.05
Pekmezaris et al. (2012) [57] 83 85 NA NA NA 42 41 1.10 (0.60–2.01) NA NA NA NA
Lyngå et al. (2012) [58] 166 153 5 8 0.56 (0.18–1.76) 79 84 0.75 (0.48–1.16) NA NA NA NA
Dendale et al. (2012) [59] 80 80 4 14 0.25 (0.08–0.79) 64 66 0.85 (0.38–1.88) 19 34 0.42 (0.21–0.83) NA
Wade et al. (2011) [60] 164 152 6 6 0.92 (0.29–2.93) 57 49 1.12 (0.70–1.79) NA NA NA
SF-36—physical health
TM −0.17; UC +1.67
p = 0.13
SF-36—mental health
TM −0.75; UC +0.04
p = 0.34
Koehler et al. (2011) [61] 354 356 54 55 0.99 (0.65–1.48) 192 179 1.17 (0.87–1.57) 64 74 0.84 (0.58–1.22)
SF-36—physical health










All-Cause Mortality All-Cause Hospitalization HF-Related Hospitalization






TM UC TM UC TM UC TM UC
Weintraub et al. (2010) [62] 95 93 1 4 0.24 (0.03–2.16) 29 31 0.88 (0.48–1.62) 10 19 0.46 (0.20–1.05) NA
Scherr et al. (2009) [63] 66 54 0 1 0.27 (0.01–6.72) 8 17 0.30 (0.12–0.77) 11 17 0.44 (0.18–1.03) NA
Mortara et al. (2009) [24] 101 160 8 9 1.44 (0.54–3.87) 35 48 1.24 (0.73–2.10) 18 28 1.02 (0.53–1.96) NA
Giordano et al. (2009) [62] 138 142 11 26 0.39 (0.18–0.82) 67 96 0.57 (0.39–0.84) 43 73 0.49 (0.32–0.76) NA














Soran et al. (2008) [67] 160 155 11 17 0.60 (0.27–1.32) 75 66 1.19 (0.76–1.86) 30 37 0.74 (0.43–1.27)
SF-12—physical health
TM 32.3; UC 33.0
p = 0.51
SF-12—mental health




TM 60.2; UC 59.9
p = 0.92
Kashem et al. (2008) [68] 24 24 1 1 1.00 (0.06–16.97) NA NA NA 2 10 0.13 (0.02–0.67)






Antonicelli et al. (2008) [70] 28 29 3 5 0.58 (0.12–2.68) 9 26 0.05 (0.01–0.23) NA NA NA
SF-36—health perception
TM + 31; UC + 8
p = 0.61
Cleland et al. (2005) [32] 168 85 28 20 0.65 (0.34–1.24) 80 46 0.77 (0.46–1.30) 40 24 0.79 (0.44–1.43)
Goldberg et al. (2003) [71] 138 142 11 26 0.39 (0.18–0.82) 65 67 1.00 (0.62–1.59) NA NA NA
SF-36—physical health
TM + 6.7; UC + 4.3
p = 0.15
SF-36—mental health
TM + 5.9; UC + 5.2
p = 0.73
Benatar et al. (2003) [72] 108 108 NA NA NA NA NA NA 13 24 0.48 (0.23–1.00)
MLWHFQ
TM − 21.5; UC − 26.3
p = 0.98
Jerant et al. (2001) [42] 13 12 0 0 Not estimable 9 12 0.08 (0.00–1.77) 1 4 0.17 (0.02–1.78)
de Lusignan et al. (2001) [73] 10 10 2 3 0.58 (0.07–4.56) NA NA NA NA NA NA
GHQ
RM − 4; UC − 7
p = NS
CI, confidence interval; EQ-5D, EuroQoL 5D; GHQ, general health questionnaire; KCCQ, Kansas City Cardiomyopathy Questionnaire; MLWHFQ, Minnesota Living with Heart Failure Questionnaire; NA, not
available; NS, not significant; OR, odds ratio; PHQ-9, patient health questionnaire-9; SF-12, Short Form survey 12-item; SF-36, Short Form survey 36-item; TM, telemonitoring; UC, usual care.
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Figure 5. All-cause hospitalization in patients receiving non-invasive telemonitoring versus usual care.
Figure 6. HF-related hospitalizations in patients receiving non-invasive telemonitoring versus usual care.
Two of the five studies including telemonitoring strategies reported a significantly
larger improvement of symptoms compared to the standard care [54,63], while three studies
did not demonstrate a beneficial effect of non-invasive telemonitoring [32,56,61].
Only one study investigated the effect of non-invasive telemonitoring on functional
performance and did not found a beneficial effect of this intervention [48].
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5. Overview of Available Studies for Non-Invasive Remote Monitoring in Heart
Failure Management: Clinical Interpretations
As shown above, considerable heterogeneity has been observed in the reported results
of all-cause mortality, all-cause hospitalization, HF-related hospitalization, and quality of
life for both structured telephone support and non-invasive telemonitoring. Considering
all the published results, the following overall effects could be observed.
5.1. Structured Telephone Support
Based on all the published results, structured telephone support appears to have a
small beneficial effect on all-cause mortality and all-cause hospitalization rates, although
it might not be significant. In contrast, a more clear beneficial impact on the HF-related
hospitalization rates has been observed. Additionally, this remote monitoring strategy
could improve the quality of life. However, large heterogeneity has been observed between
the published studies. Several reasons might explain the observed differences. Firstly, the
number of included patients and the study design different significantly between the
studies. Additionally, we observed a clear association between the year of publication and
the treatment effect, with older studies showing more often a beneficial effect. Finally, the
heterogeneity might be explained by differences in the follow-up period. Studies using a
shorter follow-up period were more likely to demonstrate a beneficial effect. The reasons
for the inconsistency in the reported results are discussed in more detail down below.
5.2. Non-Invasive Telemonitoring
Overall, non-invasive telemonitoring strategies might significantly reduce all-cause
mortality and HF-related hospitalization rates. In contrast, no significant reduction in the
all-cause hospitalization rates has been observed. The quality of life, symptom burden,
and functional performance improved in patients who received non-invasive telemoni-
toring. However, significant heterogeneity has been observed in the published results.
Studies demonstrating a beneficial effect were more likely to include patients who were
recently hospitalized for HF, representing patients with unstable HF. Additionally, studies
including a more extensive remote monitoring strategy, using multiple parameters, more
often reported a beneficial effect. Additionally, more recent published studies less often
demonstrated a beneficial effect, compared to older studies. These reasons for inconsistency
in the reported results are discussed in more detail down below.
6. Reasons for Inconsistent Results
As demonstrated, large heterogeneity in the reported effects of non-invasive remote
monitoring strategies on all-cause mortality, all-cause hospitalization, and HF-related
hospitalizations exists. Several differences in study design and patient characteristics might
explain the inconsistency in the reported results. So was the percentage of studies that
included patients who were hospitalized due to HF (e.g., unstable HF patients) lower
in studies who did not report a beneficial effect of structured telephone support or non-
invasive remote monitoring on the all-cause mortality, all-cause hospitalization, or HF-
related hospitalization rates. Hospitalization for HF is associated with an increased risk for
mortality as well as rehospitalizations [5,74]. In these unstable HF patients, non-invasive
remote monitoring has the largest potential to improve their clinical outcomes and reduce
the HF-related hospitalization rates. In contrast, stable HF patients might already be in an
ideal clinical condition, and adding non-invasive remote monitoring would not lead to
further optimization of their condition.
It has been suggested that the more recently published non-invasive remote moni-
toring studies would have a reduced benefit in preventing all-cause mortality, all-cause
hospitalization, and HF-related hospitalization rates [12]. We showed similar results, with
most studies that showed no beneficial effects of non-invasive remote monitoring were
published in 2008 or more recent. Over the last decades, cardiac imaging, diagnostic testing,
pharmacological treatment, and device therapy have evolved continuously [75]. Results
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from earlier perform studies might not reflect the current state of HF care, as indicated
by the lower uptake of the guideline-recommended background therapy in the earlier
published studies. This could have significantly impacted the results, with less optimized
patients included in the earlier studies and more optimized patients in the later studies.
Additionally, the follow-up duration in the studies ranged from one month up to
four years. We observed that most studies that demonstrated a reduction of all-cause
mortality had a follow-up period of six months or shorter. Studies with a follow-up period
longer than six months reported more often no difference in the all-cause mortality. Similar
results were found in the most recent Cochrane review [12]. These results indicate that
non-invasive remote monitoring might improve the clinical outcomes in the short term,
but that long term survival remains unaffected. Structured telephone support studies
with a follow-up period of six months or shorter reported more often a beneficial effect on
the hospitalization rates, while studies with a longer follow-up demonstrated more often
no reduction.
In contrast, such difference was not found in studies analyzing non-invasive re-
mote telemonitoring, as also have been demonstrated by the most recent Cochrane meta-
analysis [12]. Many structured telephone support monitoring strategies focused on patient
education. This could help maintain an optimal clinical state during the short term but
would be ineffective in detecting an upcoming deterioration of HF in time. Especially
since the interval of the telephone calls was only once every two weeks or even less of-
ten. In contrast, patients receiving non-invasive remote telemonitoring were instructed
to take daily readings. Therefore, in these patients, signals of imminent HF deterioration
could be detected in time, and hospitalization might be prevented, even during a longer
follow-up period.
Finally, the variables included in the non-invasive remote telemonitoring studies
varied widely. This limits the comparability of the studies and might explain some of
the observed inconsistent results. Furthermore, in some studies, adherence to the tele-
monitoring strategy declined rapidly, reducing these monitoring strategies’ effectiveness.
Improving patient participation in the monitoring strategies, ensuring that the patient per-
forms the monitoring readings daily regardless of their situation, is crucial for developing
an effective remote monitoring strategy.
7. Future Perspectives
Currently, the 2016 European Society of Cardiology (ESC) Guidelines for the diagnosis
and treatment of acute and chronic heart failure does not provide any recommendation for
the use of non-invasive remote monitoring [76]. In contrast, the use of invasive remote mon-
itoring of pulmonary artery pressures or multiparameter monitoring based on implantable
cardioverter-defibrillator may be considered (Class IIb recommendation) [76]. In contrast,
the 2013 American College of Cardiology (ACC) and American Heart Association (AHA)
Guideline for the management of heart failure recommended using effective systems to
coordinate HF care to provide the guideline-recommended medical therapy and prevent
hospitalizations (class I recommendation), although remote monitoring is not explicitly
recommended [77]. However, in the most recent updated ACC/AHA guideline of 2017, no
new recommendation on remote monitoring has been included [78]. Since more evidence
shows a beneficial effect of remote monitoring and provides incremental information that
could be used in the titration of HF treatment, we expect that in the newest guidelines
of both the ESC and ACC/AHA, remote monitoring of chronic HF patients will receive
a more specific positive recommendation. Since the more recent published studies on
non-invasive remote monitoring strategies have shown less often a beneficial effect on
preventing HF-related hospitalizations, this strategy might be more indicated to be used
in less symptomatic HF patients to guide the titration of their HF therapy. In contrast,
more invasive remote monitoring strategies could be recommended in more symptomatic
HF patients.
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The additional information, provided by non-invasive remote monitoring strategies,
can be used to prevent HF decompensations, and alert treating clinicians for an imminent
HF-related hospitalization. Currently, most studies investigating non-invasive remote
monitoring have focused on this aspect. However, these strategies are limited due to
their reactive design, leaving only a short period for the treating clinicians to react and
prevent HF-related hospitalizations [6]. Instead, an active strategy could be used as well.
Non-invasive remote monitoring could also be used to assess an ideal target for each
patient. The provided feedback could guide the medical therapy to reach and maintain
the patients as close to this target as possible, improving their clinical status, keeping
them as stable as possible, and potentially allowing for cardiac remodeling and improving
their survival [79]. Both a reactive and active strategy should not exclude each other and
should be incorporated into one remote monitoring system. Reacting to imminent HF
deterioration should be ideally coordinated from a central national center, allowing for
timely intervention. In contrast, the active strategy, consisting of optimizing the HF therapy,
should be managed by the local health care teams, who are in close contact with the
patients [80].
Furthermore, the efficacy of newly introduced HF drugs, as well as invasive proce-
dures (such as valvular interventions) could be monitored and analyzed using remote
monitoring strategies. The feedback provided by these remote monitoring strategies can
be used to better understand the (lack of) effects of these new treatment options. Addi-
tionally, the effects of treatment changes can be used to determine whether more invasive
interventions are indicated.
Recently, studies investigating invasive remote monitoring strategies have shown a
beneficial effect in more symptomatic patients [81–84]. However, these invasive strategies
are limited due to their higher costs and its invasive nature. We believe that these invasive
strategies should only be used in more symptomatic and more ill patients. Non-invasive
remote monitoring strategies are easier to be widely implemented and should be used to
monitor less symptomatic chronic HF patients.
In the future, the results from studies investigating remote monitoring in chronic HF
patients should be analyzed by a trans-disciplinary team. Thereby, new technologies, such
as artificial intelligence and machine learning, could be used to determine effective remote
monitoring strategies and could highlight new inroads for further studies.
8. Conclusions
Despite some inconsistency in the reported results on the effectiveness of non-invasive
remote monitoring in chronic HF patients, the overall combined results demonstrated a
small beneficial effect on the overall survival, HF-related hospitalizations, and adherence to
the guideline-recommended pharmacological therapy. Due to its simplicity, non-invasive
nature, and relatively low costs, non-invasive remote monitoring is desirable and to be
recommended in lower risk or less symptomatic chronic HF patients. As the volume of HF
patients is very high, the impact of non-invasive remote monitoring strategies could have a
large impact at not too high costs. More symptomatic and complex higher risk HF patients
would likely benefit more from invasive remote monitoring strategies, but at a higher cost.
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